Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agents Therapy from the ACTG A5336 Study

2021 ◽  
Author(s):  
Selwyn J. Hurwitz ◽  
Sijia Tao ◽  
Christina Gavegnano ◽  
Yong Jiang ◽  
Randall Tressler ◽  
...  
Keyword(s):  
Antiretroviral Agents

Hypersensitivity reactions induced by antiretroviral agents

Alergologia ◽  
2017 ◽  
Vol 1 (1) ◽  
Author(s):  
Corina Bocșan ◽  
Adriana Muntean ◽  
Anca Buzoianu
Keyword(s):  
Hypersensitivity Reactions ◽  
Antiretroviral Agents

An Overview of Antiretroviral Agents for Treating HIV Infection in Paediatric Population

2020 ◽  
Vol 27 (5) ◽  
pp. 760-794 ◽  
Author(s):  
Rita Melo ◽  
Agostinho Lemos ◽  
António J. Preto ◽  
Beatriz Bueschbell ◽  
Pedro Matos-Filipe ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Reverse Transcriptase ◽  
Targeted Delivery ◽  
Highly Active Antiretroviral Therapy ◽  
Antiretroviral Drugs ◽  
Viral Reservoir ◽  
Reverse Transcriptase Inhibitors ◽  
Replication Process ◽  
Antiretroviral Agents ◽  
Multiple Drugs

Paediatric Acquired ImmunoDeficiency Syndrome (AIDS) is a life-threatening and infectious disease in which the Human Immunodeficiency Virus (HIV) is mainly transmitted through Mother-To- Child Transmission (MTCT) during pregnancy, labour and delivery, or breastfeeding. This review provides an overview of the distinct therapeutic alternatives to abolish the systemic viral replication in paediatric HIV-1 infection. Numerous classes of antiretroviral agents have emerged as therapeutic tools for downregulation of different steps in the HIV replication process. These classes encompass Non- Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs), Nucleoside/Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs/NtRTIs), INtegrase Inhibitors (INIs), Protease Inhibitors (PIs), and Entry Inhibitors (EIs). Co-administration of certain antiretroviral drugs with Pharmacokinetic Enhancers (PEs) may boost the effectiveness of the primary therapeutic agent. The combination of multiple antiretroviral drug regimens (Highly Active AntiRetroviral Therapy - HAART) is currently the standard therapeutic approach for HIV infection. So far, the use of HAART offers the best opportunity for prolonged and maximal viral suppression, and preservation of the immune system upon HIV infection. Still, the frequent administration of high doses of multiple drugs, their inefficient ability to reach the viral reservoirs in adequate doses, the development of drug resistance, and the lack of patient compliance compromise the complete HIV elimination. The development of nanotechnology-based drug delivery systems may enable targeted delivery of antiretroviral agents to inaccessible viral reservoir sites at therapeutic concentrations. In addition, the application of Computer-Aided Drug Design (CADD) approaches has provided valuable tools for the development of anti-HIV drug candidates with favourable pharmacodynamics and pharmacokinetic properties.

Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors

2017 ◽  
Vol 23 (18) ◽  
Author(s):  
Mina Psichogiou ◽  
Garyphalia Poulakou ◽  
Dimitrios Basoulis ◽  
Dimitrios Paraskevis ◽  
Antonios Markogiannakis ◽  
...  
Keyword(s):  
Integrase Inhibitors ◽  
Antiretroviral Agents ◽  
Recent Advances

Overview of Antiretroviral Agents in 2005

2005 ◽  
Vol 18 (4) ◽  
pp. 228-246 ◽  
Author(s):  
Anela Stanic ◽  
Tulip K. Schneider
Keyword(s):  
Protease Inhibitors ◽  
Transcriptase Inhibitor ◽  
Fixed Dose ◽  
Antiretroviral Agents ◽  
Entry Inhibitors ◽  
Fusion Inhibitors ◽  
Resistant Strains ◽  
Atazanavir Sulfate ◽  
Reverse Transcriptase Inhibitor ◽  
Drug Resistant Strains

To date, 25 antiretroviral agents (including fixed-dose combinations) have gained approval by the Food and Drug Administration and are currently available on the market for the treatment of HIV-1 infection. New protease inhibitors, atazanavir sulfate (Reyataz) and fosamprenavir (Lexiva), were licensed, in addition to the nucleoside analogue reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva) and 2 fixed-dose NRTI combinations, emtricitabine/tenofovir disoproxil fumarate (Truvada) and lamivudine/abacavir (Epzicom). These newly licensed antiretroviral agents allow for lower pill burden and dosing schedule simplification, and some agents such as atazanavir sulfate are associated with improved lipid profile in comparison to other currently marketed protease inhibitors. In addition, a new class of anti-retroviral agents, entry inhibitors, of which a subclass exists called fusion inhibitors with its representative member, enfuvirtide (Fuzeon), which is currently the only available drug in its class, was marketed almost 2 years ago. Despite a remarkable progress in the treatment of HIV infection noted during the past decade, significant challenges to therapy such as tolerability issues and emergence of drug-resistant strains remain. Therefore, new antiretroviral drug development has focused on a design of drugs that work against the resistant strains of HIV and/or have a novel mechanism of action.

Antiretroviral Agents: Looking for the Best Possible Chemotherapeutic Options to Conquer HIV

2016 ◽  
Vol 26 (4) ◽  
pp. 363-381 ◽  
Author(s):  
Tahir Farooq ◽  
Arruje Hameed ◽  
Kanwal Rehman ◽  
Muhammad Ibrahim ◽  
Muhammad Imran Qadir ◽  
...  
Keyword(s):  
Antiretroviral Agents

scholarly journals Synergistic In Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20)

2006 ◽  
Vol 50 (6) ◽  
pp. 2231-2233 ◽  
Author(s):  
Xing-Quan Zhang ◽  
Meredith Sorensen ◽  
Michael Fung ◽  
Robert T. Schooley
Keyword(s):  
Viral Replication ◽  
Viral Entry ◽  
Antiretroviral Agents ◽  
Entry Inhibitors ◽  
High Level ◽  
Antiretroviral Activity

ABSTRACT Recently, antiretroviral agents directed at several steps involved in viral entry have been shown to reduce viral replication in vitro and in vivo. We have demonstrated a high level of in vitro synergistic antiretroviral activity for two entry inhibitors that are directed at sequential steps in the entry process.

A Review of Commonly Prescribed Antiviral and Antiretroviral Agents

2011 ◽  
Vol 27 (3) ◽  
pp. 99-110
Author(s):  
Hanine Mansour ◽  
Lisa Devito Inge ◽  
Jason Ferreira ◽  
Nathan R Unger
Keyword(s):  
Antiretroviral Agents
Sign in / Sign up

Export Citation Format

Share Document